International Journal of Pharmaceutical Science Invention (IJPSI) is an international journal intended for professionals and researchers in all fields of Pahrmaceutical Science. IJPSI publishes research articles and reviews within the whole field Pharmacy and Pharmaceutical Science, new teaching methods, assessment, validation and the impact of new technologies and it will continue to provide information on the latest trends and developments in this ever-expanding subject. The publications of papers are selected through double peer reviewed to ensure originality, relevance, and readability. The articles published in our journal can be accessed online.
Development of immune checkpoint inhibitors for treating various cancer disea...SriramNagarajan16
Cancer is a state which involves an abnormal increase in the number of cells, with a potentiality to invade or spread to
other parts of the body and destroy their function. Every individual is born with an immune system that acts as a
security checkpoint. The immune system does possess B and T lymphocytes, B -cells acts as the military intelligence
and T-cells acts as soldiers it also possesses some receptors that scan normal cells and abnormal cells like a virus and
some other cells. Abnormal cells are detected and removed by the T-cells, but in some conditions, T-cells fail to detect
and eliminate cancer cells. This is because of higher mutations in cancer cells leads to a development of some of the
receptors like PD-L1 which acts as the signal jammer of the T-cell. This leads to failure in the work of T-cells against
the cancer cells not only this some other receptors like CTLA-4 of T-Cells acts as a type of “off switch” to keep the
immune system in off. Immune checkpoint inhibitors are used by targeting PD-1, PD-L1 and CTLA-4 targets and drugs
like pembrolizumab, nivolumab, ipilimumab and etc. are used to treat various types of cancer.
T cell Immune Pathways Current and Future Implementation in Cancer Immunother...CrimsonpublishersCancer
T cells are central players in cancer immune response. The discovery of T cell immune pathways has revealed several inhibitory and stimulatory pathways that affect the differentiation and activation of T cell. Theses pathways represent ideal candidates that can be targeted to augment in-vivo. T cell immune response against tumors. In this mini review we will try to reveal some inhibitory and stimulatory T cell immune pathways to which efforts of those interested in cancer immunotherapy can be directed.
2020 regulatory mechanism of micro rna expression in cancerAntar
This document summarizes how microRNA (miRNA) expression is deregulated in cancer. It discusses how genetic and epigenetic alterations can dysregulate miRNA expression at the transcriptional and post-transcriptional levels. Specifically, it describes how transcription factors like p53, RREB1, C/EBPβ, and c-Myc can modulate miRNA expression and impact cancer processes. It also explains how epigenetic changes like DNA methylation and histone modifications at miRNA gene promoters can alter miRNA expression patterns in cancer. Understanding these regulatory mechanisms of miRNA expression is important for elucidating their roles in cancer pathogenesis.
Cytokines are proteins involved in cell signaling and communication that are important in immune responses and inflammation. They are produced by immune cells and modulate processes like immune cell development, activation of lymphocytes and phagocytes, and the inflammatory response. Cytokines play roles in diseases like cancer, rheumatoid arthritis, sepsis, and tuberculosis by influencing processes such as immune cell recruitment and activation, tissue damage, and granuloma formation. Their levels can provide information about disease activity and progression in some conditions.
In 3 sentences:
Envigo is a global contract research organization dedicated to helping customers advance human and animal health. They provide contract research services and research models across 5 continents, employing over 3,800 people at 52 locations. The presentation discussed key considerations for the non-clinical safety evaluation of drugs targeting immune checkpoints, including challenges assessing immunotoxicity and predicting autoimmune risks in animal models.
More information about this activity can be found here: http://bit.ly/ST0uRp
Chairperson
Jedd D. Wolchok, MD, PhD
Memorial Sloan-Kettering Cancer Center
Faculty
Antoni Ribas, MD, PhD
University of California, Los Angeles
Mary L. Disis, MD
University of Washington School of Medicine
Charles G. Drake, MD, PhD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
John Powderly II, MD, CPI
Carolina BioOncology Institute, PLLC
Cancer Therapy & Research Center
Activity Overview
Advances in basic immunology have led to an improved understanding of the interactions between the immune system and tumors, generating renewed interest in novel immunologic approaches to the treatment of cancer. Indeed, there have been multiple FDA approvals of immunologic agents in recent years and there are many ongoing trials of novel immunotherapies in lung cancer, colorectal cancer, and other tumor types.
In this series of half-day conferences, leading oncologists will provide an overview of immune system–cancer interactions, the safety and efficacy of recently approved immunologic agents for the treatment of melanoma and prostate cancer, the latest data from ongoing trials in non-small cell lung cancer, colorectal cancer, and others, and the management of immune-related adverse events (IRAEs). These sessions will include case studies to stimulate interactive discussion of real-world treatment scenarios.
Learning Objectives
Upon completion of this activity, participants should be better able to:
• Describe the biological foundations of immunotherapy approaches to the
treatment of cancer
• Identify the mechanisms of action of immuno-oncologic agents such as
vaccines and immune system-modulating antibodies
• Evaluate new safety and efficacy data on recently approved and emerging
immunotherapies across tumor types
• Describe how new immunotherapies are integrated into existing treatment
evidence-based guidelines
• Identify ongoing research efforts in immuno-oncology including how to
appropriately select patients who would be candidates for clinical trials
More information about this activity can be found here: http://bit.ly/ST0uRp
Maytansinoid immunoconjugate IMGN901 is cytotoxicEllen Gunn
IMGN901 is a maytansinoid immunoconjugate targeting CD56, which is expressed in 70% of multiple myeloma cases. The study evaluated IMGN901 alone and in combination with lenalidomide and dexamethasone to determine if it can overcome environmental-mediated drug resistance (EM-DR) in multiple myeloma. While adhesion to extracellular matrix reduced IMGN901 potency, it remained cytotoxic with an LC50 of 43 nM. However, only a combination of IMGN901, lenalidomide, and dexamethasone was able to overcome drug resistance arising from direct contact between multiple myeloma and stromal cells. Drug resistance in this condition was associated with upregulation of multi-drug
This document discusses breaking immune tolerance to cancer (melanoma) by targeting regulatory T cells (Tregs). It suggests that Tregs suppress anti-tumor immune responses by secreting cytokines like TGF-β and IL-10. Depleting Tregs using cyclophosphamide or blocking CTLA-4 with ipilimumab can help activate the immune system. However, some tumors lack "danger signals" like inflammatory cytokines needed to recruit T cells. Stimulating toll-like receptor 4 on macrophages may induce cytokines like IL-6, IL-1β, and TNFα that create an inflammatory microenvironment and promote anti-tumor immunity.
Development of immune checkpoint inhibitors for treating various cancer disea...SriramNagarajan16
Cancer is a state which involves an abnormal increase in the number of cells, with a potentiality to invade or spread to
other parts of the body and destroy their function. Every individual is born with an immune system that acts as a
security checkpoint. The immune system does possess B and T lymphocytes, B -cells acts as the military intelligence
and T-cells acts as soldiers it also possesses some receptors that scan normal cells and abnormal cells like a virus and
some other cells. Abnormal cells are detected and removed by the T-cells, but in some conditions, T-cells fail to detect
and eliminate cancer cells. This is because of higher mutations in cancer cells leads to a development of some of the
receptors like PD-L1 which acts as the signal jammer of the T-cell. This leads to failure in the work of T-cells against
the cancer cells not only this some other receptors like CTLA-4 of T-Cells acts as a type of “off switch” to keep the
immune system in off. Immune checkpoint inhibitors are used by targeting PD-1, PD-L1 and CTLA-4 targets and drugs
like pembrolizumab, nivolumab, ipilimumab and etc. are used to treat various types of cancer.
T cell Immune Pathways Current and Future Implementation in Cancer Immunother...CrimsonpublishersCancer
T cells are central players in cancer immune response. The discovery of T cell immune pathways has revealed several inhibitory and stimulatory pathways that affect the differentiation and activation of T cell. Theses pathways represent ideal candidates that can be targeted to augment in-vivo. T cell immune response against tumors. In this mini review we will try to reveal some inhibitory and stimulatory T cell immune pathways to which efforts of those interested in cancer immunotherapy can be directed.
2020 regulatory mechanism of micro rna expression in cancerAntar
This document summarizes how microRNA (miRNA) expression is deregulated in cancer. It discusses how genetic and epigenetic alterations can dysregulate miRNA expression at the transcriptional and post-transcriptional levels. Specifically, it describes how transcription factors like p53, RREB1, C/EBPβ, and c-Myc can modulate miRNA expression and impact cancer processes. It also explains how epigenetic changes like DNA methylation and histone modifications at miRNA gene promoters can alter miRNA expression patterns in cancer. Understanding these regulatory mechanisms of miRNA expression is important for elucidating their roles in cancer pathogenesis.
Cytokines are proteins involved in cell signaling and communication that are important in immune responses and inflammation. They are produced by immune cells and modulate processes like immune cell development, activation of lymphocytes and phagocytes, and the inflammatory response. Cytokines play roles in diseases like cancer, rheumatoid arthritis, sepsis, and tuberculosis by influencing processes such as immune cell recruitment and activation, tissue damage, and granuloma formation. Their levels can provide information about disease activity and progression in some conditions.
In 3 sentences:
Envigo is a global contract research organization dedicated to helping customers advance human and animal health. They provide contract research services and research models across 5 continents, employing over 3,800 people at 52 locations. The presentation discussed key considerations for the non-clinical safety evaluation of drugs targeting immune checkpoints, including challenges assessing immunotoxicity and predicting autoimmune risks in animal models.
More information about this activity can be found here: http://bit.ly/ST0uRp
Chairperson
Jedd D. Wolchok, MD, PhD
Memorial Sloan-Kettering Cancer Center
Faculty
Antoni Ribas, MD, PhD
University of California, Los Angeles
Mary L. Disis, MD
University of Washington School of Medicine
Charles G. Drake, MD, PhD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
John Powderly II, MD, CPI
Carolina BioOncology Institute, PLLC
Cancer Therapy & Research Center
Activity Overview
Advances in basic immunology have led to an improved understanding of the interactions between the immune system and tumors, generating renewed interest in novel immunologic approaches to the treatment of cancer. Indeed, there have been multiple FDA approvals of immunologic agents in recent years and there are many ongoing trials of novel immunotherapies in lung cancer, colorectal cancer, and other tumor types.
In this series of half-day conferences, leading oncologists will provide an overview of immune system–cancer interactions, the safety and efficacy of recently approved immunologic agents for the treatment of melanoma and prostate cancer, the latest data from ongoing trials in non-small cell lung cancer, colorectal cancer, and others, and the management of immune-related adverse events (IRAEs). These sessions will include case studies to stimulate interactive discussion of real-world treatment scenarios.
Learning Objectives
Upon completion of this activity, participants should be better able to:
• Describe the biological foundations of immunotherapy approaches to the
treatment of cancer
• Identify the mechanisms of action of immuno-oncologic agents such as
vaccines and immune system-modulating antibodies
• Evaluate new safety and efficacy data on recently approved and emerging
immunotherapies across tumor types
• Describe how new immunotherapies are integrated into existing treatment
evidence-based guidelines
• Identify ongoing research efforts in immuno-oncology including how to
appropriately select patients who would be candidates for clinical trials
More information about this activity can be found here: http://bit.ly/ST0uRp
Maytansinoid immunoconjugate IMGN901 is cytotoxicEllen Gunn
IMGN901 is a maytansinoid immunoconjugate targeting CD56, which is expressed in 70% of multiple myeloma cases. The study evaluated IMGN901 alone and in combination with lenalidomide and dexamethasone to determine if it can overcome environmental-mediated drug resistance (EM-DR) in multiple myeloma. While adhesion to extracellular matrix reduced IMGN901 potency, it remained cytotoxic with an LC50 of 43 nM. However, only a combination of IMGN901, lenalidomide, and dexamethasone was able to overcome drug resistance arising from direct contact between multiple myeloma and stromal cells. Drug resistance in this condition was associated with upregulation of multi-drug
This document discusses breaking immune tolerance to cancer (melanoma) by targeting regulatory T cells (Tregs). It suggests that Tregs suppress anti-tumor immune responses by secreting cytokines like TGF-β and IL-10. Depleting Tregs using cyclophosphamide or blocking CTLA-4 with ipilimumab can help activate the immune system. However, some tumors lack "danger signals" like inflammatory cytokines needed to recruit T cells. Stimulating toll-like receptor 4 on macrophages may induce cytokines like IL-6, IL-1β, and TNFα that create an inflammatory microenvironment and promote anti-tumor immunity.
A talk presented by Prof. Mohamed Labib Salem at Minofia University محاضرة للأستاذ الدكتور محمد لبيب سالم جامعة طنطا يوم الثلاثاء السادس عشر من فبراير بجامعة المنوفية
Keys of Success in Research: Tanta University, Egypt as a Case study
Center of Excellence in Cancer Research
Grants, Innovation & Technology Transfer Center
n overview of current immunotherapy therapies used to treat cancer. Also provides MOA of various medications, and updates on SITC guidelines for metastatice melanoma.
ROLE OF IMMUNE CELLS IN CANCER AND TARGETING IMMUNE CELLS FOR CANCER THERAPYSIVASWAROOP YARASI
Immune cells like macrophages, neutrophils, natural killer cells, T cells, B cells, and cytokines in the tumor microenvironment can either promote or inhibit cancer progression. Adoptive cell immunotherapy uses tumor-infiltrating lymphocytes, cytotoxic T lymphocytes, or chimeric antigen receptor T/NK cells to target cancers. Clinical trials are exploring these immunotherapies for various solid tumors and hematological malignancies, though challenges remain for treating solid tumors due to the immunosuppressive tumor microenvironment.
CTLA-4: IMMUNE CHECKPOINT BLOCKADE THERAPY,,,, THE 2018 NOBEL PRIZE WINNING STUDY IN THE FIELD OF PHYSIOLOGY/ MEDICINE,,, JOINTLY AWARDED TO JAMES P. ALLISON OF USA and TASAKU HONJU OF JAPAN .
This document summarizes recent advances in immunotherapy for solid tumors. It discusses how immunotherapy has established itself as an effective treatment strategy, building on William Coley's pioneering work in the late 1800s using bacteria to elicit anti-tumor immune responses. The document outlines several key immunotherapy approaches, including immune checkpoint inhibitors, adoptive cellular therapy, strategies to enhance tumor immunogenicity like radiotherapy and oncolytic viruses, and cancer vaccines. It also discusses how tumor-infiltrating lymphocytes and immunoscore can help predict cancer prognosis and how the immune system interacts with tumors.
This document discusses recent advances in cancer immunotherapy. It describes how improved understanding of immunology has led to new immunotherapies using toll-like receptor agonists, T cells, NK cells, dendritic cells, and monoclonal antibodies. Major cellular immunotherapies discussed include using T cells activated outside the body with cytokines like IL-2, and engineering T cells to express tumor-targeting receptors.
- Certain miRNAs, such as miR-21 and miR-34a, show potential as biomarkers for the diagnosis and prognosis of pancreatic ductal adenocarcinoma (PDAC) as their expression levels correlate with cancer progression and patient survival.
- Inhibiting overexpressed miRNAs in PDAC, such as miR-21, miR-221 and miR-222, using antagomirs delivered via lipoplex nanoparticles reduced tumor cell proliferation, invasion and restored chemosensitivity in cell line studies.
- Epithelial-mesenchymal transition (EMT), which is regulated by transcription factors and miRNAs and promotes metastasis, plays an important role in PDAC development. Controlling pathways involved in EMT
Effectiveness of Resveratrol on Metastasis: A Reviewiosrphr_editor
The IOSR Journal of Pharmacy (IOSRPHR) is an open access online & offline peer reviewed international journal, which publishes innovative research papers, reviews, mini-reviews, short communications and notes dealing with Pharmaceutical Sciences( Pharmaceutical Technology, Pharmaceutics, Biopharmaceutics, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy & Phytochemistry, Pharmacology, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest........more details on Aim & Scope).
1) CAR T cells specific for CD19 have shown remarkable success in treating blood cancers but have had limited effect on solid tumors which lack the CD19 antigen.
2) The IMPACT technology uses fusion proteins containing the extracellular domain of CD19 linked to single-chain antibodies targeting other antigens to bridge CAR19 T cells to solid tumors.
3) Experiments showed CAR19 T cells redirected by a CD19-anti-HER2 fusion protein were cytotoxic against HER2-positive ovarian cancer cells in vitro, demonstrating the IMPACT technology can redirect CAR T cells to new tumor targets through antigen bridging.
This document summarizes principles of cancer chemotherapy and immunosuppressant drugs. It discusses how chemotherapy aims to cause cytotoxic effects in cancer cells through DNA damage or inhibiting cell replication. Common side effects include vomiting, bone marrow suppression and hair loss. It also outlines mechanisms of immunosuppressants like cyclosporine, tacrolimus and sirolimus which inhibit T-cell activation and cytokine production to prevent transplant rejection. Specific adverse effects and therapeutic uses of different classes of chemotherapeutics and immunosuppressants are also summarized.
This document discusses microRNAs (miRNAs), which are small non-coding RNAs that negatively regulate gene expression and play important roles in cellular processes and cancer. MiRNAs can function as oncogenes or tumor suppressors depending on their target genes. They show deregulation in many cancers and have potential as cancer therapeutics. Current miRNA therapy approaches involve inhibiting oncogenic miRNAs using anti-miRs or restoring tumor suppressive miRNAs using mimics. Various modified oligonucleotides and molecular strategies are used to target specific miRNAs. Some miRNA-based drugs are currently in clinical trials for different cancer types.
Slides of my graded Advanced Immunology presentation. Outlines melanoma vaccine strategies in an easy-to-read way.
Vaccinology, University of the Witwatersrand, Johannesburg, South Africa.
This document summarizes a literature review on intra-tumoral lymphocytes (TIL) in breast cancer. The review found that assessing TIL is unnecessary in high-grade tumors but may be useful in intermediate-grade tumors. In neoadjuvant and adjuvant settings, CD3+ lymphocytes correlate with better response to chemotherapy. After chemotherapy, quantifying regulatory T cells (Treg; CD4+FOXP3+) is helpful as decreased levels correlate with better prognosis. While the role of TIL in breast cancer is established, the optimal methods for microscopic assessment and immunohistochemical subtyping of TIL remain unclear.
Cancer immunotherapy nivedita shah msc.biotech- 13937eureka1
This document provides an overview of cancer immunotherapy. It discusses how immunotherapy harnesses the immune system to fight cancer through techniques like monoclonal antibodies, cytokines, adoptive cell therapy, and cancer vaccines. Monoclonal antibodies target specific antigens on cancer cells, while cytokines are proteins that serve as messenger molecules between immune cells. Adoptive cell therapy transfers immune cells back into patients to improve immune function against tumors. Cancer vaccines stimulate the immune system to attack existing or prevent future cancer cells. The document also outlines some limitations of immunotherapy approaches and notes how cancer immunotherapy was named Breakthrough of the Year by the journal Science in 2013.
This document discusses adaptive immunity in cancer therapies. It provides an overview of the history of cancer immunotherapy from ancient times to modern immunotherapy approaches. It describes the key players in the anti-tumor immune response including T cells, B cells, macrophages, and dendritic cells. Different immune-based therapy approaches are summarized, including monoclonal antibodies, cytokines, vaccines, manipulation of costimulatory signals, blocking inhibitory pathways, adoptive T cell therapy, and oncolytic virotherapy. The conclusion states that immunotherapy has shown effectiveness for some cancer types but has not been proven as an effective sole treatment for cancer.
This document discusses new strategies for combating cancer through molecular biology approaches. It describes prevention strategies that focus on pre-invasive lesions by inhibiting carcinogen initiation events, cell proliferation associated with promotion, or the development of the invasive phenotype in precancerous lesions. Targets for prevention strategies include biochemical species produced by carcinogens and aberrantly expressed proteins from genetic/environmental risk factors. Gene expression profiling using cDNA microarrays can help understand carcinogenesis at the molecular level and identify new therapeutic targets. The document also discusses inhibiting metastasis through strategies like modifying cell adhesion with MMP inhibitors or anticoagulants, and inhibiting angiogenesis. Gene therapy approaches for cancer treatment aim to correct genetic mutations or deliver therapeutic genes to stimulate anti-tumor immune
This document provides an overview of immunotherapy for cancer. It discusses how immunotherapy works by boosting the body's natural immune response against cancer cells. The main types of immunotherapy discussed are monoclonal antibodies, cancer vaccines, and non-specific immunotherapies like cytokines and interferons. Monoclonal antibodies are engineered antibodies that target specific antigens on cancer cells, while cancer vaccines are designed to trigger an immune response against tumor antigens. Together, these immunotherapies help the immune system better recognize and destroy cancer cells.
Immunological Abnormalities in Liver CarcinomaAnik Banik
1) Hepatocellular carcinoma (HCC) has a poor prognosis and limited treatment options. While immune therapies show promise, the response of HCC has been unsatisfactory due to its immunosuppressive microenvironment.
2) Dendritic cells activate T cells to target cancer cells, but in HCC various immune cells and cytokines like regulatory T cells and TGF-β promote immune suppression.
3) Future therapies aim to modulate this microenvironment through vaccines, adoptive cell transfer, immune checkpoint blockade, and other approaches to achieve effective anti-tumor immunity against HCC.
This document provides instructions for setting up a Facebook advertising campaign, including choosing an objective, account information, target audience, daily budget, creating ads with photos, and desktop and mobile ad views. It also includes a link to an article about changes to Facebook ad campaigns.
A talk presented by Prof. Mohamed Labib Salem at Minofia University محاضرة للأستاذ الدكتور محمد لبيب سالم جامعة طنطا يوم الثلاثاء السادس عشر من فبراير بجامعة المنوفية
Keys of Success in Research: Tanta University, Egypt as a Case study
Center of Excellence in Cancer Research
Grants, Innovation & Technology Transfer Center
n overview of current immunotherapy therapies used to treat cancer. Also provides MOA of various medications, and updates on SITC guidelines for metastatice melanoma.
ROLE OF IMMUNE CELLS IN CANCER AND TARGETING IMMUNE CELLS FOR CANCER THERAPYSIVASWAROOP YARASI
Immune cells like macrophages, neutrophils, natural killer cells, T cells, B cells, and cytokines in the tumor microenvironment can either promote or inhibit cancer progression. Adoptive cell immunotherapy uses tumor-infiltrating lymphocytes, cytotoxic T lymphocytes, or chimeric antigen receptor T/NK cells to target cancers. Clinical trials are exploring these immunotherapies for various solid tumors and hematological malignancies, though challenges remain for treating solid tumors due to the immunosuppressive tumor microenvironment.
CTLA-4: IMMUNE CHECKPOINT BLOCKADE THERAPY,,,, THE 2018 NOBEL PRIZE WINNING STUDY IN THE FIELD OF PHYSIOLOGY/ MEDICINE,,, JOINTLY AWARDED TO JAMES P. ALLISON OF USA and TASAKU HONJU OF JAPAN .
This document summarizes recent advances in immunotherapy for solid tumors. It discusses how immunotherapy has established itself as an effective treatment strategy, building on William Coley's pioneering work in the late 1800s using bacteria to elicit anti-tumor immune responses. The document outlines several key immunotherapy approaches, including immune checkpoint inhibitors, adoptive cellular therapy, strategies to enhance tumor immunogenicity like radiotherapy and oncolytic viruses, and cancer vaccines. It also discusses how tumor-infiltrating lymphocytes and immunoscore can help predict cancer prognosis and how the immune system interacts with tumors.
This document discusses recent advances in cancer immunotherapy. It describes how improved understanding of immunology has led to new immunotherapies using toll-like receptor agonists, T cells, NK cells, dendritic cells, and monoclonal antibodies. Major cellular immunotherapies discussed include using T cells activated outside the body with cytokines like IL-2, and engineering T cells to express tumor-targeting receptors.
- Certain miRNAs, such as miR-21 and miR-34a, show potential as biomarkers for the diagnosis and prognosis of pancreatic ductal adenocarcinoma (PDAC) as their expression levels correlate with cancer progression and patient survival.
- Inhibiting overexpressed miRNAs in PDAC, such as miR-21, miR-221 and miR-222, using antagomirs delivered via lipoplex nanoparticles reduced tumor cell proliferation, invasion and restored chemosensitivity in cell line studies.
- Epithelial-mesenchymal transition (EMT), which is regulated by transcription factors and miRNAs and promotes metastasis, plays an important role in PDAC development. Controlling pathways involved in EMT
Effectiveness of Resveratrol on Metastasis: A Reviewiosrphr_editor
The IOSR Journal of Pharmacy (IOSRPHR) is an open access online & offline peer reviewed international journal, which publishes innovative research papers, reviews, mini-reviews, short communications and notes dealing with Pharmaceutical Sciences( Pharmaceutical Technology, Pharmaceutics, Biopharmaceutics, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy & Phytochemistry, Pharmacology, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest........more details on Aim & Scope).
1) CAR T cells specific for CD19 have shown remarkable success in treating blood cancers but have had limited effect on solid tumors which lack the CD19 antigen.
2) The IMPACT technology uses fusion proteins containing the extracellular domain of CD19 linked to single-chain antibodies targeting other antigens to bridge CAR19 T cells to solid tumors.
3) Experiments showed CAR19 T cells redirected by a CD19-anti-HER2 fusion protein were cytotoxic against HER2-positive ovarian cancer cells in vitro, demonstrating the IMPACT technology can redirect CAR T cells to new tumor targets through antigen bridging.
This document summarizes principles of cancer chemotherapy and immunosuppressant drugs. It discusses how chemotherapy aims to cause cytotoxic effects in cancer cells through DNA damage or inhibiting cell replication. Common side effects include vomiting, bone marrow suppression and hair loss. It also outlines mechanisms of immunosuppressants like cyclosporine, tacrolimus and sirolimus which inhibit T-cell activation and cytokine production to prevent transplant rejection. Specific adverse effects and therapeutic uses of different classes of chemotherapeutics and immunosuppressants are also summarized.
This document discusses microRNAs (miRNAs), which are small non-coding RNAs that negatively regulate gene expression and play important roles in cellular processes and cancer. MiRNAs can function as oncogenes or tumor suppressors depending on their target genes. They show deregulation in many cancers and have potential as cancer therapeutics. Current miRNA therapy approaches involve inhibiting oncogenic miRNAs using anti-miRs or restoring tumor suppressive miRNAs using mimics. Various modified oligonucleotides and molecular strategies are used to target specific miRNAs. Some miRNA-based drugs are currently in clinical trials for different cancer types.
Slides of my graded Advanced Immunology presentation. Outlines melanoma vaccine strategies in an easy-to-read way.
Vaccinology, University of the Witwatersrand, Johannesburg, South Africa.
This document summarizes a literature review on intra-tumoral lymphocytes (TIL) in breast cancer. The review found that assessing TIL is unnecessary in high-grade tumors but may be useful in intermediate-grade tumors. In neoadjuvant and adjuvant settings, CD3+ lymphocytes correlate with better response to chemotherapy. After chemotherapy, quantifying regulatory T cells (Treg; CD4+FOXP3+) is helpful as decreased levels correlate with better prognosis. While the role of TIL in breast cancer is established, the optimal methods for microscopic assessment and immunohistochemical subtyping of TIL remain unclear.
Cancer immunotherapy nivedita shah msc.biotech- 13937eureka1
This document provides an overview of cancer immunotherapy. It discusses how immunotherapy harnesses the immune system to fight cancer through techniques like monoclonal antibodies, cytokines, adoptive cell therapy, and cancer vaccines. Monoclonal antibodies target specific antigens on cancer cells, while cytokines are proteins that serve as messenger molecules between immune cells. Adoptive cell therapy transfers immune cells back into patients to improve immune function against tumors. Cancer vaccines stimulate the immune system to attack existing or prevent future cancer cells. The document also outlines some limitations of immunotherapy approaches and notes how cancer immunotherapy was named Breakthrough of the Year by the journal Science in 2013.
This document discusses adaptive immunity in cancer therapies. It provides an overview of the history of cancer immunotherapy from ancient times to modern immunotherapy approaches. It describes the key players in the anti-tumor immune response including T cells, B cells, macrophages, and dendritic cells. Different immune-based therapy approaches are summarized, including monoclonal antibodies, cytokines, vaccines, manipulation of costimulatory signals, blocking inhibitory pathways, adoptive T cell therapy, and oncolytic virotherapy. The conclusion states that immunotherapy has shown effectiveness for some cancer types but has not been proven as an effective sole treatment for cancer.
This document discusses new strategies for combating cancer through molecular biology approaches. It describes prevention strategies that focus on pre-invasive lesions by inhibiting carcinogen initiation events, cell proliferation associated with promotion, or the development of the invasive phenotype in precancerous lesions. Targets for prevention strategies include biochemical species produced by carcinogens and aberrantly expressed proteins from genetic/environmental risk factors. Gene expression profiling using cDNA microarrays can help understand carcinogenesis at the molecular level and identify new therapeutic targets. The document also discusses inhibiting metastasis through strategies like modifying cell adhesion with MMP inhibitors or anticoagulants, and inhibiting angiogenesis. Gene therapy approaches for cancer treatment aim to correct genetic mutations or deliver therapeutic genes to stimulate anti-tumor immune
This document provides an overview of immunotherapy for cancer. It discusses how immunotherapy works by boosting the body's natural immune response against cancer cells. The main types of immunotherapy discussed are monoclonal antibodies, cancer vaccines, and non-specific immunotherapies like cytokines and interferons. Monoclonal antibodies are engineered antibodies that target specific antigens on cancer cells, while cancer vaccines are designed to trigger an immune response against tumor antigens. Together, these immunotherapies help the immune system better recognize and destroy cancer cells.
Immunological Abnormalities in Liver CarcinomaAnik Banik
1) Hepatocellular carcinoma (HCC) has a poor prognosis and limited treatment options. While immune therapies show promise, the response of HCC has been unsatisfactory due to its immunosuppressive microenvironment.
2) Dendritic cells activate T cells to target cancer cells, but in HCC various immune cells and cytokines like regulatory T cells and TGF-β promote immune suppression.
3) Future therapies aim to modulate this microenvironment through vaccines, adoptive cell transfer, immune checkpoint blockade, and other approaches to achieve effective anti-tumor immunity against HCC.
This document provides instructions for setting up a Facebook advertising campaign, including choosing an objective, account information, target audience, daily budget, creating ads with photos, and desktop and mobile ad views. It also includes a link to an article about changes to Facebook ad campaigns.
Blue Ribbon Bacon Festival 2015-Bacons South of I-80 by Leo Landisleolandis
This document discusses bacon production in Iowa. It provides the following key details:
1) As of December 2014, there were 20.9 million hogs in Iowa, far outnumbering the state's 3 million human population.
2) In the late 19th century, Iowa began producing huge numbers of hogs, rising from 323,247 hogs in 1850 to over 57 million hogs in 1890.
3) Traditional bacon was cured using recipes from the 18th-19th centuries. Modern processors use brine injectors and smokehouses to produce bacon on a larger scale.
Factory and mine work in the past was extremely dangerous, with thousands dying each year from accidents. Workers faced long 16-hour shifts with low wages, and only one day off per week. Child labor was also common, with children performing hazardous jobs. Both factory and mine workers faced severe health risks from poor conditions, regularly suffering lung disease and losing limbs. Miners faced additional dangers from explosions and floods. Living conditions for workers and their families were terrible, with overcrowded housing lacking clean water or adequate sewerage.
This document appears to be a quiz for a logistics course covering topics in Chapter 10 related to transportation procurement and supply chain management. It consists of 26 multiple choice questions testing understanding of key concepts like the goals of transportation procurement, trends in transportation modes, challenges faced by different carriers, and important freight documents. The quiz covers topics like outsourcing, intermodal growth, carrier competition, and transportation efficiency.
1) The document shows calculations to determine the moment of inertia and polar moment of inertia of a rectangular area about different axes. It is shown that the moment of inertia about one end of the rectangle can be used as the polar moment of inertia at a point where the polar radius is small compared to a characteristic length.
2) Moment of inertia calculations are shown for a shaded area using a differential element approach about the x- and y- axes.
3) Further calculations are presented to determine the rectangular and polar moments of inertia of another shaded area about different axes and a point.
Camia Patino is an entrepreneur and photographer born in 1991 in New Jersey but raised in Colombia. She has a passion for spirit science, entertainment, art, traveling, and acquiring knowledge. Her skills include being a photographer specializing in weddings and fashion, being trilingual, and having experience in event planning, creative writing, and customer service roles like personal assistant and photography supervisor. Her work goals include having challenges, productivity, meaning, and flexibility.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive functioning. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
Evaluating the use of Social Networking Sites as a Tool for Knowledge Sharing...Dr Elaine Garcia
This document summarizes a study that evaluated the use of social networking sites (SNS) like Facebook to facilitate knowledge sharing in higher education institutions in Egypt and Iraq. It found that while SNS showed potential, there were also challenges to adoption. Both institutions lacked clear knowledge sharing strategies and had differing levels of cultural acceptance of and technological barriers to SNS use. The study concluded that an institutional approach is needed that addresses strategies, management support, technological issues, and cultural/social factors specific to each context.
Este documento fornece orientações sobre o preenchimento e estrutura do arquivo da Escrituração Contábil Digital (ECD) de acordo com a legislação brasileira. Ele explica os requisitos técnicos para geração do arquivo ECD, incluindo blocos, registros, tabelas e códigos, além de detalhar as informações que devem ser lançadas em cada registro.
Restrictive clauses limit the meaning of the subject they refer to, while non-restrictive clauses provide additional information about the subject without limiting its meaning. A restrictive clause is essential to identify which room is being referred to, as in "The room on the first floor is the largest one," while a non-restrictive clause adds extra details, like calling a room "your favorite," without that information being essential to understand which room is meant.
The document describes the FitDesk system, a wellness program that allows members to view and track workouts, health evaluations, and communicate with trainers online or through a kiosk. It discusses features for booking, tracking fitness, and retaining members. One health club saw retention increase from 73.5% after implementing FitDesk to 80.4% over 4 years as it helped support, educate, and engage members.
Mantra Lighting is a leading Spanish manufacturer of top quality lighting fixtures, and as one of the largest distributors of Mantra lighting in the North of England, Lighting at Home stock an extensive collection of Mantra lighting products at incredible prices. Our collection of Mantra lighting products includes an incredible range of different designs and products, including table lamps, wall lights, ceiling fixtures, low energy light fittings, and many more.
Mantra Lighting produces dozens of different lighting ranges, each available in a range of different colours, styles and finishes. From the contemporary designs of the Cocoon and Sintesys ranges, to the more traditional styles such as the Siena collection, and the minimalist models from the Comfort range. No matter what style of lighting fixtures you'd prefer for your home or office, Mantra Lighting products are the ideal choice.
All of our Mantra lighting products are available to view and order online here at the Lighting at Home website, as well as being on display in our fantastic lighting showroom in Manchester. When you order your Mantra lighting products online, we will aim to dispatch them from our warehouse the next working day, with free delivery available on orders over £75 for UK Mainland.
Whether you need a stylish new ceiling fixture for your living room, or you're looking to cut down on your energy emissions with some sophisticated low energy lighting products, you're sure to find the right products from our Mantra lighting range to suit both your style needs and your budget.
Este documento presenta tres puntos clave:
1) Explica el contexto del pasaje del Evangelio de Mateo sobre el nacimiento de Jesús y la aparición del ángel a José.
2) Señala que Mateo incluye citas del Antiguo Testamento para mostrar que Jesús cumple las profecías.
3) Analiza la profecía de Isaías sobre Emmanuel que Mateo aplica a Jesús, explicando el contexto histórico en que se produjo.
Immunological Checkpoints and Cancer Immunotherapyimgcommcall
Immunological checkpoints and cancer immunotherapy were reviewed. Immune checkpoint inhibitors like anti-CTLA-4 and anti-PD-1/PD-L1 antibodies can activate the immune system against cancer by blocking inhibitory signals to T cells. Clinical trials show these drugs produce durable responses in various cancers like melanoma, lung cancer, and Merkel cell carcinoma. Combining different immunotherapies or with other treatments may help more patients by overcoming resistance. Ongoing research aims to better understand combination approaches and biomarkers of response.
This document summarizes two scientific articles about Programmed Death-1 (PD-1) and its ligands PD-L1 and PD-L2. The first article analyzes the basal and induced expression of PD-1 ligands in three chordoma cell lines and finds that while basal expression is low, expression is upregulated by IFN-γ but not IL-4. The second article examines blocking the PD-1/PD-L1 pathway to prevent loss of effector function in adoptively transferred central memory CD8+ T cells against tumors.
PD-L1 is a protein that is expressed on tumor cells and suppresses the immune system's ability to attack tumors. Blocking the PD-1/PD-L1 pathway through antibodies or other inhibitors can help the immune system recognize and destroy cancer cells. Several PD-L1 antibody drugs have been approved to treat cancers like lung cancer and urothelial carcinoma. Clinical trials are also testing combinations of PD-L1 inhibitors with other cancer therapies to improve treatment outcomes. Researchers continue to develop new approaches for targeting the PD-1/PD-L1 pathway, including gene silencing techniques and pathway inhibitors.
1) The combination of the HDAC inhibitor entinostat and anti-PD-1 antibody significantly inhibited tumor growth in a murine renal cell carcinoma model more than either treatment alone.
2) Analysis of the tumor microenvironment showed the combination increased CD8+ T cells and decreased regulatory T cells, resulting in an increased CD8+/Treg ratio.
3) The combination also increased two subsets of myeloid-derived suppressor cells in the tumor and altered tumor-associated macrophages and CD8+ T cells, indicating changes to the immune cell populations in the microenvironment.
The document discusses PD-L1 expression in gliomas and the potential for blocking the PD-1/PD-L1 pathway as a new treatment strategy. It summarizes that PD-L1 is expressed in glioma cell lines and tumor tissues in approximately 44% of cases based on various studies. Higher PD-L1 expression is correlated with higher glioma grade. Blocking the PD-1/PD-L1 pathway has shown encouraging results in other cancers and offers hope as a new immunotherapy for gliomas given the role of this pathway in glioma progression and limiting the immune response against the tumors.
PD1PDL1 Pathway and its inhibitors for slideshare.pptxdrshrikantraut
PD-1 and its ligand PD-L1 act as an immune checkpoint that inhibits T cell activation and allows tumors to evade immune detection. Blocking this pathway with monoclonal antibodies such as nivolumab and pembrolizumab has shown clinical efficacy in cancer treatment. A meta-analysis of over 28,000 cancer patients found that PD-1/PD-L1 inhibitors achieved an overall response rate of 20.21% and higher response rates in PD-L1 positive versus negative tumors. PD-1/PD-L1 blockade also improved progression-free and overall survival more in PD-L1 positive patients compared to conventional therapies. However, predictive biomarkers beyond PD-L1 expression are still needed to
The document discusses anti-cancer immunity from an immune perspective. It covers topics like cancer immunoediting, how cancer cells become resistant to immune elimination, and different anti-cancer immunotherapy strategies. Specifically:
1) Cancers evolve to escape immune detection through a process called immunoediting where immunogenic tumor cells are eliminated, leaving behind immune-resistant cells.
2) Tumor cells can become resistant by losing antigen expression or failing to present antigens on MHC molecules, allowing them to evade T cell attack.
3) Popular immunotherapies include immune checkpoint blockade, adoptive cell transfer, vaccines, and strategies that non-specifically stimulate the immune system.
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...Mark Lipstein
This document summarizes a study examining the combination of a novel PI3Kδ inhibitor, TGR-1202, with the proteasome inhibitor carfilzomib for treating hematological malignancies. The study found that TGR-1202 synergizes strongly with carfilzomib in lymphoma, leukemia, and myeloma cell lines and primary cells by silencing c-Myc translation. This synergistic effect is driven by TGR-1202's unexpected additional activity of inhibiting CK1ε, which contributes to repressing phosphorylation of 4E-BP1 and lowering c-Myc protein levels. The results suggest that TGR-1202, as a dual PI3Kδ/CK1ε inhibitor, may have
1) The document discusses tumor immunology and mechanisms of tumor immune evasion. It describes how tumors can downregulate MHC expression, secrete immunosuppressive factors, inhibit T cell function through checkpoint pathways like PD-1/PD-L1, and recruit immunosuppressive cells like Tregs.
2) Checkpoint pathways like CTLA-4 and PD-1 normally regulate T cell activation, but tumors can exploit these pathways to evade immune destruction by overexpressing ligands that bind these inhibitory receptors.
3) Several immunotherapies targeting CTLA-4 and PD-1/PD-L1 have been developed including ipilimumab, nivolumab, pembrol
1. The document describes the development of a Meso Scale Discovery (MSD) assay to quantify the concentration of PD-1 antibody in mouse serum and tumor samples.
2. The researchers optimized variables such as the PD-1 antigen coating concentration and detection antibody concentration to create an assay with high sensitivity down to 0.5 ng/mL, low background, and minimal matrix interference.
3. Using this MSD assay, they evaluated the pharmacokinetics of a PD-1 antibody called RMP1-14 in tumor-bearing mice and found dose proportional exposure in serum and a strong correlation between serum and tumor antibody levels.
The Role of Immunity in Chemotherapy-Resistant Patient with Pembrolizumab: A ...daranisaha
This case report describes a chemotherapy-resistant NSCLC patient who did not respond to pembrolizumab therapy. Immunological indicators showed decreased CD4+ and CD8+ T cells and increased myeloid-derived suppressor cells during treatment. Examination of tumor tissue found low CD8+ T cell infiltration and PD-1 expression. Despite two cycles of pembrolizumab, the patient's condition progressed rapidly and he died of respiratory failure after 6 months. The detection of immunological indicators may help predict response to PD-1 antibody therapy.
Here we present a case report of a NSCLC patient had not benefited from Pembrolizumab therapy following chemotherapy. We reviewed the treatment and clinical examination profiles, especially the Immunological indicators. In the ending stage, the patient appeared
pneumonia, respiratory failure, septicemia, gastrointestinal hemorrhage, and hypoproteinemia.
The percentage of CD4+ and CD8+ T cell in peripheral blood were decreased companion the
expression of PD-1. However, the percentage of MDSC (myeloid-derived suppressor cells) was
increased continuously. We also detected the expression of PD-1 on T cell in pleural effusion
that was under the average value of 24 cases and in the tumor site that was the same with the
pleural effusion. Besides the detected CD8+ T lymphocyte infiltration was very low. The overall
survival was 6 mouths.
The Role of Immunity in Chemotherapy-Resistant Patient with Pembrolizumab: A ...semualkaira
Approaches are limited for treating advanced Non-Small-Cell Lung Cancer (NSCLC) with multidrug resistance but without ALK and EGFR mutations. Pembrolizumab (KEYTRUDA) brings on unprecedented clinical benefit in various cancer types.
The Role of Immunity in Chemotherapy-Resistant Patient with Pembrolizumab: A ...ClinicsofOncology
Approaches are limited for treating advanced Non-Small-Cell Lung Cancer (NSCLC) with multidrug resistance but without ALK and EGFR mutations. Pembrolizumab (KEYTRUDA) brings on unprecedented clinical benefit in various cancer types
The Role of Immunity in Chemotherapy-Resistant Patient with Pembrolizumab: A ...semualkaira
Approaches are limited for treating advanced Non-Small-Cell Lung Cancer (NSCLC) with multidrug resistance but without ALK and EGFR mutations. Pembrolizumab (KEYTRUDA) brings on unprecedented clinical benefit in various cancer types
The Role of Immunity in Chemotherapy-Resistant Patient with Pembrolizumab: A ...JohnJulie1
Approaches are limited for treating advanced Non-Small-Cell Lung Cancer (NSCLC) with multidrug resistance but without ALK and EGFR mutations. Pembrolizumab (KEYTRUDA) brings on unprecedented clinical benefit in various cancer types...
The Role of Immunity in Chemotherapy-Resistant Patient with Pembrolizumab: A ...NainaAnon
Approaches are limited for treating advanced Non-Small-Cell Lung Cancer (NSCLC) with multidrug resistance but without ALK and EGFR mutations. Pembrolizumab (KEYTRUDA) brings on unprecedented clinical benefit in various cancer types..
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...Donc Test
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
1. International Journal of Pharmaceutical Science Invention
ISSN (Online): 2319 – 6718, ISSN (Print): 2319 – 670X
www.ijpsi.org || Volume 3 Issue 12 || December 2014 || PP.31-38
www.ijpsi.org 31 | Page
Antitumor Mechanisms of Immune Checkpoints PD-L1/PD-1
Blockade in Cancer Treatment
1,
Xu Deng, 2,
Juan Liu , 3,
Yuan Wang , 4,
Changping Wu , 5,
Jingting Jiang
Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University; Cancer
Immunotherapy Engineering Research Center of Jiangsu Province, Changzhou 213003, China
ABSTRACT : Programmed death-1 (PD-1) and its ligand (programmed death ligand 1, PD-L1) are negative
regulators of immunity. They play a negative role in regulating immune response through interacting with
immune cells, resulting in inhibited antitumor response. Tumor immunotherapy with PD-1 or PD-L1 antibody
has been shown to be capable of prolonging survival of cancer patients and improving their life quality. Here we
summarize the role of PD-L1/PD-1 in regulating immune response, antitumor mechanism and application of
PD-L1/PD-1 blockade in cancer treatment.
KEY WORDS: PD-L1/PD-1, Immune checkpoints blockade, Antibody, Tumor immunotherapy
I. INTRODUCTION
Previous researches demonstrate that tumor cells could evade host immune surveillance by several
strategies, including down-regulation of cell surface major histocompatibility complex I molecules [1,
2],secretion of immunosuppressive factors[3, 4], lack of T-cell costimulation [5, 6], and expression of death
ligands or negative ligands[7, 8]. Programmed death-1 (PD-1) is a inducible receptor present on T cells and
macrophages and plays a critical role in the negative regulation of immune responses[9]. Engagement of PD-1
by PD-L1 leads to the inhibition of TCR-mediated lymphocyte proliferation and cytokine secretion[10].
Immune checkpoint blockade could enhance anti-tumor immune response by blocking interaction between PD-
L1 and PD-1 with antibody against PD-L1 or PD-1[11]. Immune checkpoint blockade in cancer therapy can
induce tumor regression, prolong survival time and improve patients’ life quality in lung cancer, melanoma and
renal carcinoma, etc [12-18]. However, besides elicitation of antitumor immune response, immune checkpoint
blockade is also associated with certain side-effects [12, 17, 18]. Therefore, it’s still a challenge to enhance the
antitumor immune response and at the same time reduce or eliminate side-effects during cancer immunotherapy.
Biological characteristics of PD-L1/PD-1 : PD-1, a member of the CD28 superfamily, is a 50-55 KDa type I
transmembrane glycoprotein[19]. PD-1 is present on cell surface as a monomer, and the intracellular part of PD-
1 contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based
switch motif (ITSM). Both motifs have a phosphorylated tyrosine when PD-1 is engaged, but only
phosphorylation of tyrosine in the C-terminus of ITIM is a critical step for PD-1 function. Recruitment of
tyrosine phosphatase SHP-1/2 after ITSM phosphorylation plays a negative role by dephosphorylating
downstream effector molecules[20-22]. PD-1 is induced on many types of immune cells, including regulatory T
cells (Tregs), activated CD4 and CD8 T cells, B cells, dendritic cells (DCs), mononuclear cells and myeloid
cells[19, 23, 24].PD-L1 (also known as B7-H1) and PD-L2 (also known as B7-DC) are the PD-1 ligands[10,
25], which share 21–27% amino acid identity and a structural organization that consists of a signal sequence,
IgV-like, IgC-like and transmembrane domains and a short cytoplasmic tail[25]. PD-L1 is selectively expressed
on many tumors including lung, ovarian, melanoma, and renal tumors[26-28], and on cells within the tumor
2. Antitumor Mechanisms Of Immune Checkpoints…
www.ijpsi.org 32 | Page
microenvironment in response to inflammatory stimuli such as resting B cells, T cells,dendrtic cells[25, 28,
29]. Both preclinical and clinical trials have shown that the expression level of PD-L1 in malignant tumors like
non-small cell lung cancer, gastric cancer and pancreatic cancer is significantly higher than that in adjacent or
normal tissues[30-32]. PD-L2 is primarily expressed on myeloid dendritic cells (mDC) and monocytes in human
heart, pancreas, lung and liver [25].
II. PD-L1/PD-1 REGULATION IN IMMUNE CELLS
T cells : Previous studies demonstrated that PD-1 up-regulation on spontaneous antigen-specific CD8+
T cells
occurs with T cell activation[33-35]. Blockade of PD-1/PD-L1 pathway augmented the frequencies of cytokine
production, proliferation and total antigen-specific CD8+
T cell[33, 36], which suggests that PD-1 may be a
regulator of antigen-specific CD8+
T cells expansion[34, 35]. Blockade of the interaction between PD-1 and its
ligands can promote the expansion of memory cells and CD4+
T cells, and cytokine secretion[37], suggesting
PD-1 may play a negative regulatory role in immune response of memory cells and activated CD4+
T cells.
When co-cultured with allogeneic CD4+
T cells, more CD4+
CD25+
Foxp3+
Treg are induced by murine
liver-derived DCs with high PD-L1 expression. However, PD-L1-deficient murine DCs fail to trigger
CD4+
CD25+
Foxp3+
Treg expansion[38] , which indicates that the effects of DCs on CD4+
CD25+
Foxp3+
Treg
induction and expansion are dependent on the PD-L1/PD-1 signaling pathway. It has been reported that TILs
had increased PD-1 expression, and PD-1 on TILs can impair their immune function, including reducing
cytokine production capability and impairing capacity to proliferate, by engaging PD-L1 in the tumor
microenvironment[39, 40]. Blockade of PD-L1 or PD-1 can partially enhance T-cell function, tumor cell lysis,
cytokine production and cell proliferation[40, 41]. Muenst et al.[42] found that PD-1 was positive in the TILs in
104 out of 660 breast cancer cases, and the expression level was associated with tumor size, grade, lymph node
status and intrinsic subtypes of breast cancer.
DCs : PD-1 is expressed in activated DCs and can decrease the survival time of DCs and inhibit its ability of
antigen presentation[24]. In wild type mice, LPS induces the expression level of PD-1 in DCs and apoptosis,
while DCs from PD-1-deficient mice are resistant to apoptosis induced by LPS[24]. Moreover, PD-1 antibody
can prolong the survival time of DCs during the process of maturation, suggesting that the PD-L1/PD-1
signaling pathway is involved in regulation of DC apoptosis[24].
Natural killer (NK) cells : Kit+
CD11b-NK cells express high PD-L1 and accumulate in lymphoid organs of
cancer patients [43]. Adaptive transfer of Kit+
CD11b-
NK cells can promote tumor growth in pulmonary
metastasis mouse models and significantly reduce dendritic and NK cell pools [43]. However, PD-1 is absent in
normal NK cells but expressed on NK cells from multiple myeloma (MM) patients. Engagement of PD-1 with
PD-L1 down-regulates NK cells against MM cells. CT-011, a novel antibody against PD-1, can enhance NK cell
function against MM cells through affecting formation of immune complex and inducing cytoxicity in PD-L1+
MM cells[44].
3. Antitumor Mechanisms Of Immune Checkpoints…
www.ijpsi.org 33 | Page
Figure 1. Effects of PD-L1/PD-1 on immune cells
III. ANTITUMOR MECHANISMS OF PD-L1/PD-1
PD-L1 is up-regulated and highly expressed in human tumor tissues due to the effects of inflammatory
cytokines, such as IFN-γ, GM-CSF, IL-4 and LPS, etc. Through binding with PD-L1 or PD-L2, PD-1 inhibits
cytokine production and the cytolytic activity of PD-1+
tumor-infiltrating CD4+
and CD8+
T cells [17]. Both
early preclinical and clinical trials of a fully human mAb against PD-1 have demonstrated clinical activity in
patients with advanced melanoma and other cancers, associated with generally manageable side
effects[45].Experiment in mice with advanced lymphoma showed that monocytic myeloid cells induced after
adoptive transfer (AT) of tumor-specific CD4+
T cells following cyclophosphamide treatment (CTX+CD4 AT)
could mediate functional tolerization of antitumor CD4+
effector cells through PD-L1/PD-1 pathway, resulting
inhibited long-term tumor control and subsequent relapse. Blockade of PD-L1/PD-1 after CTX+CD4 AT therapy
led to persistence of CD4+
effector cells and durable antitumor effects[46].
By detecting PD-1 expression on CD8+
T cells from both healthy control and NSCLC patients’
peripheral blood mononuclear cells, Zhang et al.[40] found that PD-1 expression on tumor infiltrating CD8+
T
cells was up-regulated, and the immune function, such as cytokine production capacity and ability to proliferate,
of PD-1high
CD8+
T cells was impaired. Blockade of PD-1/PD-L1 pathway partially restored cell proliferation
and cytokine production, suggesting that PD-L1/PD-1 signaling is involved in CD8+
T cell dysfunction. It has
also been identified that low level of PD-1 was constitutively expressed on iNKT cells. Blockade of PD-L1/PD-
1 pathway can not only prevent the induction of anergy in iNKT cells but also restore responsiveness of anergic
iNKT cells, and production of IFN-γ, IL-4 and IL-2 by iNKT cells was also elevated[47]. Blockade of PD-L1 on
myeloid dendritic cells (MDCs) could also enhance MDC-mediated T-cell activation and was accompanied by
downregulation of T-cell IL-10 and upregulation of IL-2 and IFN-γ. T cells conditioned with the B7-H1-
blockade MDCs had a more potent ability to inhibit tumor growth in mice model [48].
IV. CLINICALAPPLICATION OF PD-L1/PD-1 CHECKPOINT BLOCKADE THERAPY
Blockade of PD-L1/PD-1 has been widely applied in tumor clinical treatment. Expression level of PD-
L1 in malignant tumor, such as HCC, melanoma, gastric cancer and pancreatic cancer, shows a negative
correlation with tumor size and prognosis [42, 49, 50]. It has been shown that overall and progression-free
survival rates for the high PD-L1 expression group were significantly lower than those for the low-expression
group, demonstrating that PD-L1 expression in tumor cells is correlated inversely with the prognosis of patients
with malignant melanoma and that PD-L1 expression is an independent prognostic factor for both overall and
progression-free survival in these patients[50].
4. Antitumor Mechanisms Of Immune Checkpoints…
www.ijpsi.org 34 | Page
PD-L1/PD-1 blockades by specific monoclonal antibodies have been shown to reverse tumor-induced
T cell exhaustion/dysfunction in patients with advanced melanoma [33], and potentiate or restore therapeutic
anticancer immunity [51]. Blocking PD-L1 signaling allows longer persistence and enhanced infiltration of T
cells into PD-L1-expressing tumor, indicating that this approach may be valuable as a means to enhance the
therapeutic efficacy of combination immunotherapy against with melanoma[36]. PD-L1 expression was
observed on more aggressive renal tumors[52], and PD-1 expression on tumor-infiltrating lymphocytes in Renal
Cell Cancer (RCC) patients has proved to be associated with more advanced cancer and reduced overall
survival[53]. Furthermore, high levels of soluble PD-L1 in the serum of RCC patients have been associated with
larger tumors of advanced stages and grades and reduced survival. Anti-PD-1 antibodies has already shown
promising studies in clinical trials including RCC patients, and the cumulative responses rates is 27% among
patients with renal-cell cancer (9 of 33 patients)[18]. Increased OS of RCC patients treated with bevacizumab in
combination with Interferon-α was observed in two phase III studies, which indicates maximal benefit for RCC
patients is likely to be achieved when immunotherapy is combined with targeted agents [54-56].
Expression of B7-H1 and B7-DC were found in both the plasma and cytoplasm of cancer cells from
surgically resected non small cell lung cancer (NSCLC) specimen [57, 58], but not in adjacent normal
tissues[59]. However, conclusions derived from present data on the prevalence and prognostic role of PD-L1
expression in NSCLC are full of controversies. Some studies showed that PD-L1 was associated with
histological types and overall survival, and might be a poor prognostic factor[59-61]. However, others indicates
PD-L1 are of no independent prognostic value[58, 62, 63]. Clinical trials demonstrated that antibodies specific
for PD-L1/PD-1 had promising antitumor efficacy in patients with NSCLC[17, 18]. Cumulative response rates
were 18% among patients with non-small-cell lung cancer (14 of 76 patients), objective responses were
observed across non–small-cell histologic types: in 6 of 18 patients (33%) with squamous tumors, 7 of 56 (12%)
with non-squamous tumors, and 1 of 2 with tumors of unknown type [18]. Although PD-L1 positive tumors are
expected to be more responsive to PD-1/PD-L1 inhibitors, particularly in tumors with high PD-L1 expression,
responses in patients with PD-L1 negative tumors ranges from 3% to 20%[63]. Kim et al.[64] found that
expression of PD-1 in soft tissue sarcoma (STS) cells is significantly associated with advanced clinic
pathological parameters, including clinical stage, presence of distant metastasis, histological grade etc. It has
been demonstrated that the infiltration of PD-1 positive lymphocytes and PD-L1 expression in STS cells are
novel prognostic indicators for STS, and the expression levels of PD-L1 and PD-1 may provide new criteria for
inclusion and exclusion of immune checkpoint PD-L1/PD-1 blockade therapy in STS clinical treatment.
V. CONCLUSION
Though immunotherapy targeting PD-L1/PD-1 has achieved great successes in many recent clinical
trials, the underlying mechanisms regarding the antitumor effect of PD-L1/PD-1 signaling pathway remain to be
explored. Both preclinical and clinical trials should focus on simplifying courses of treatment and reducing
associated side-effects. Moreover, antineoplastic drugs should be reasonably applied to improve antitumor
function of immune checkpoint blockade therapy. Altogether, treatment based on immune checkpoint PD-
L1/PD-1 will definitely provide new strategies for cancer immunotherapy.
5. Antitumor Mechanisms Of Immune Checkpoints…
www.ijpsi.org 35 | Page
Competing interests : The authors declare that they have no competing interests.
AUTHORS’ CONTRIBUTIONS
Xu Deng did the research work on PubMed and drafted the manuscript. Juan Liu and Yuan Wang
revised the manuscript. Jingting Jiang and Changping Wu provided the conceptual design of the study, and
edited final version of the manuscript. All authors have read and approved final manuscript.
Funding sources : This research project was supported by the National Natural Science Foundation of China
(NSFC) (81171653), Natural Science Foundation of Jiangsu Province (BK2011246 and BK2011247), and
Jiangsu Provincial Innovation Award BC2012093 by the Bureau of Science and Technology of Jiangsu
Province.
REFERENCES
[1] Yamazaki K, Spruill G, Rhoderick J, Spielman J, Savaraj N, Podack ER: Small cell lung carcinomas express shared and private tumor
antigens presented by HLA-A1 or HLA-A2. Cancer research 1999, 59(18):4642-4650.
[2] Redondo M, Concha A, Oldiviela R, Cueto A, Gonzalez A, Garrido F, Ruiz-Cabello F: Expression of HLA class I and II antigens in
bronchogenic carcinomas: its relationship to cellular DNA content and clinical-pathological parameters. Cancer research 1991,
51(18):4948-4954.
[3] Samuels V, Barrett JM, Bockman S, Pantazis CG, Allen MB, Jr.: Immunocytochemical study of transforming growth factor expression
in benign and malignant gliomas. The American journal of pathology 1989, 134(4):894-902.
[4] Huettner C, Paulus W, Roggendorf W: Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. The
American journal of pathology 1995, 146(2):317-322.
[5] Wu TC, Huang AY, Jaffee EM, Levitsky HI, Pardoll DM: A reassessment of the role of B7-1 expression in tumor rejection. The Journal
of experimental medicine 1995, 182(5):1415-1421.
[6] Smyth MJ, Godfrey DI, Trapani JA: A fresh look at tumor immunosurveillance and immunotherapy. Nature immunology 2001,
2(4):293-299.
[7] Oizumi S, Yamazaki K, Nakashima M, Watanabe T, Hommura F, Ogura S, Nishimura M, Dosaka-Akita H: RCAS1 expression: a
potential prognostic marker for adenocarcinomas of the lung. Oncology 2002, 62(4):333-339.
[8] Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D et al: Melanoma
cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996, 274(5291):1363-1366.
[9] Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ: Programmed death-1 ligand 1 interacts specifically with the B7-1
costimulatory molecule to inhibit T cell responses. Immunity 2007, 27(1):111-122.
[10] Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC et al:
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte
activation. The Journal of experimental medicine 2000, 192(7):1027-1034.
[11] Ribas A: Tumor Immunotherapy Directed at PD-1. The New England journal of medicine 2012, 366(26):2517-2519.
[12] Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS et al: Safety and tumor
responses with lambrolizumab (anti-PD-1) in melanoma. The New England journal of medicine 2013, 369(2):134-144.
[13] Gunturi A, McDermott DF: Potential of New Therapies like Anti-PD1 in Kidney Cancer. Current treatment options in oncology 2014,
15(1):137-146.
[14] Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L et al: Durable cancer regression
off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clinical cancer research : an official journal of the
American Association for Cancer Research 2013, 19(2):462-468.
[15] Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al:
Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine 2010, 363(8):711-
6. Antitumor Mechanisms Of Immune Checkpoints…
www.ijpsi.org 36 | Page
723.
[16] Riley JL: Combination checkpoint blockade--taking melanoma immunotherapy to the next level. The New England journal of
medicine 2013, 369(2):187-189.
[17] Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K et al: Safety and
activity of anti-PD-L1 antibody in patients with advanced cancer. The New England journal of medicine 2012, 366(26):2455-2465.
[18] Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et
al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine 2012, 366(26):2443-
2454.
[19] Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T: Expression of the PD-1 antigen on the surface of
stimulated mouse T and B lymphocytes. International immunology 1996, 8(5):765-772.
[20] Ishida Y, Agata Y, Shibahara K, Honjo T: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon
programmed cell death. The EMBO journal 1992, 11(11):3887-3895.
[21] Nirschl CJ, Drake CG: Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for
cancer immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research 2013,
19(18):4917-4924.
[22] Francisco LM, Sage PT, Sharpe AH: The PD-1 pathway in tolerance and autoimmunity. Immunological reviews 2010, 236:219-242.
[23] Okudaira K, Hokari R, Tsuzuki Y, Okada Y, Komoto S, Watanabe C, Kurihara C, Kawaguchi A, Nagao S, Azuma M et al: Blockade of
B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. International journal of oncology 2009, 35(4):741-
749.
[24] Park SJ, Namkoong H, Doh J, Choi JC, Yang BG, Park Y, Chul Sung Y: Negative role of inducible PD-1 on survival of activated
dendritic cells. Journal of leukocyte biology 2013.
[25] Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R et al: PD-L2 is a
second ligand for PD-1 and inhibits T cell activation. Nature immunology 2001, 2(3):261-268.
[26] Zou W, Chen L: Inhibitory B7-family molecules in the tumour microenvironment. Nature reviews Immunology 2008, 8(6):467-477.
[27] Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M et al: Clinical
significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007, 13(7):2151-2157.
[28] Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K et al: Tumor-associated B7-H1
promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature medicine 2002, 8(8):793-800.
[29] Dong H, Zhu G, Tamada K, Chen L: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10
secretion. Nature medicine 1999, 5(12):1365-1369.
[30] Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL:
Programmed death ligand-1 expression in non-small cell lung cancer. Laboratory investigation; a journal of technical methods and
pathology 2014, 94(1):107-116.
[31] Chen XL, Yuan SX, Chen C, Mao YX, Xu G, Wang XY: [Expression of B7-H1 protein in human pancreatic carcinoma tissues and its
clinical significance]. Ai zheng = Aizheng = Chinese journal of cancer 2009, 28(12):1328-1332.
[32] Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N: Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in
gastric carcinoma and its clinical significance. Acta histochemica 2006, 108(1):19-24.
[33] Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM: Upregulation of Tim-3
and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. The Journal of
experimental medicine 2010, 207(10):2175-2186.
[34] Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E, Adams WC, Precopio ML, Schacker T, Roederer M, Douek DC et al: PD-
1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. The Journal of experimental medicine 2006, 203(10):2281-
2292.
7. Antitumor Mechanisms Of Immune Checkpoints…
www.ijpsi.org 37 | Page
[35] Petrovas C, Price DA, Mattapallil J, Ambrozak DR, Geldmacher C, Cecchinato V, Vaccari M, Tryniszewska E, Gostick E, Roederer M
et al: SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic
SIVmac251 infection. Blood 2007, 110(3):928-936.
[36] Pilon-Thomas S, Mackay A, Vohra N, Mule JJ: Blockade of programmed death ligand 1 enhances the therapeutic efficacy of
combination immunotherapy against melanoma. J Immunol 2010, 184(7):3442-3449.
[37] Cai G, Karni A, Oliveira EM, Weiner HL, Hafler DA, Freeman GJ: PD-1 ligands, negative regulators for activation of naive, memory,
and recently activated human CD4+ T cells. Cellular immunology 2004, 230(2):89-98.
[38] Liu H, Bakthavatsalam R, Meng Z, Li Z, Li W, Perkins JD, Reyes J: PD-L1 signal on liver dendritic cells is critical for
Foxp3(+)CD4(+)CD25(+) Treg and liver tolerance induction in mice. Transplantation proceedings 2013, 45(5):1853-1855.
[39] Inozume T, Hanada K, Wang QJ, Ahmadzadeh M, Wunderlich JR, Rosenberg SA, Yang JC: Selection of CD8+PD-1+ lymphocytes in
fresh human melanomas enriches for tumor-reactive T cells. J Immunother 2010, 33(9):956-964.
[40] Zhang Y, Huang S, Gong D, Qin Y, Shen Q: Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating
CD8+ T lymphocytes in human non-small cell lung cancer. Cellular & molecular immunology 2010, 7(5):389-395.
[41] McDermott DF, Atkins MB: PD-1 as a potential target in cancer therapy. Cancer medicine 2013, 2(5):662-673.
[42] Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE: The presence of programmed death 1 (PD-1)-positive tumor-
infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast cancer research and treatment 2013,
139(3):667-676.
[43] Terme M, Ullrich E, Aymeric L, Meinhardt K, Coudert JD, Desbois M, Ghiringhelli F, Viaud S, Ryffel B, Yagita H et al: Cancer-
induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer research 2012, 72(11):2757-2767.
[44] Benson DM, Jr., Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK et al: The PD-
1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal
anti-PD-1 antibody. Blood 2010, 116(13):2286-2294.
[45] Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL et al: Phase I
study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics,
and immunologic correlates. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010,
28(19):3167-3175.
[46] Ding ZC, Lu X, Yu M, Lemos H, Huang L, Chandler P, Liu K, Walters M, Krasinski A, Mack M et al: Immunosuppressive myeloid
cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis. Cancer research 2014,
74(13):3441-3453.
[47] Chang WS, Kim JY, Kim YJ, Kim YS, Lee JM, Azuma M, Yagita H, Kang CY: Cutting edge: Programmed death-1/programmed death
ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. J Immunol 2008, 181(10):6707-6710.
[48] Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC et al: Blockade of
B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nature medicine 2003, 9(5):562-567.
[49] Wang L, Ma Q, Chen X, Guo K, Li J, Zhang M: Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma. World
journal of surgery 2010, 34(5):1059-1065.
[50] Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, Okazaki T, Tokura Y: Tumor cell expression of programmed cell death-
1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010, 116(7):1757-1766.
[51] Oba J, Nakahara T, Abe T, Hagihara A, Moroi Y, Furue M: Expression of programmed death receptor ligand 1 in melanoma may
indicate tumor progression and poor patient survival. Journal of the American Academy of Dermatology 2014, 70(5):954-956.
[52] Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H et al: Tumor
B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer research 2006, 66(7):3381-
3385.
[53] Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Kwon ED: PD-1 is expressed by tumor-infiltrating
immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clinical cancer research : an official journal
8. Antitumor Mechanisms Of Immune Checkpoints…
www.ijpsi.org 38 | Page
of the American Association for Cancer Research 2007, 13(6):1757-1761.
[54] Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V: Phase III trial of
bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010, 28(13):2144-2150.
[55] Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J et al: Phase III trial
of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of
CALGB 90206. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010, 28(13):2137-2143.
[56] Bedke J, Gouttefangeas C, Singh-Jasuja H, Stevanovic S, Behnes CL, Stenzl A: Targeted therapy in renal cell carcinoma: moving from
molecular agents to specific immunotherapy. World journal of urology 2014, 32(1):31-38.
[57] Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, Salomao D, Cheville J, Hirano F, Lin W et al: B7-H1 blockade
augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer research 2003, 63(19):6501-6505.
[58] Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M: B7-H1 expression on non-small cell lung cancer cells
and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clinical cancer research : an official journal of the
American Association for Cancer Research 2004, 10(15):5094-5100.
[59] Mu CY, Huang JA, Chen Y, Chen C, Zhang XG: High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor
cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011, 28(3):682-688.
[60] Chen YB, Mu CY, Huang JA: Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung
cancer: a 5-year-follow-up study. Tumori 2012, 98(6):751-755.
[61] Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M et al: Association of
PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Annals of oncology : official
journal of the European Society for Medical Oncology / ESMO 2014.
[62] Boland JM, Kwon ED, Harrington SM, Wampfler JA, Tang H, Yang P, Aubry MC: Tumor B7-H1 and B7-H3 expression in squamous
cell carcinoma of the lung. Clinical lung cancer 2013, 14(2):157-163.
[63] Gettinger S, Herbst RS: B7-H1/PD-1 Blockade Therapy in Non-Small Cell Lung Cancer: Current Status and Future Direction. Cancer
J 2014, 20(4):281-289.
[64] Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Kim KM, Park HS, Lee H, Moon WS, Chung MJ et al: Tumor Infiltrating PD1-
Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas. PloS one 2013, 8(12):e82870.